Combined Transcriptome and Circulating Tumor DNA Longitudinal Biomarker Analysis Associates With Clinical Outcomes in Advanced Solid Tumors Treated With Pembrolizumab.

Alberto Hernando-Calvo, S Y Cindy Yang, Maria Vila-Casadesús, Ming Han, Zhihui Amy Liu, A Hal K Berman, Anna Spreafico, Albiruni Abdul Razak, Stephanie Lheureux, Aaron R Hansen, Deborah Lo Giacco, Farnoosh Abbas-Aghababazadeh, Judith Matito, Benjamin Haibe-Kains, Trevor J Pugh

August 2024 JCO Precis Oncol

Synopsis of Social media discussions

Participants mainly express positive reception and recognition of the study's potential, calling it a 'significant' or 'innovative' approach, with phrases such as 'associates with clinical outcomes' and references to the article's relevance for personalized medicine. The tone is predominantly informative and hopeful, signaling a belief in the study's importance but with some engaged also discussing specific biomarkers like VIGex and ctDNA that hint at deeper interest and understanding.

A
Agreement
 Moderate agreement

Most discussions acknowledge the importance of the study, highlighting its contribution to personalized cancer treatment and biomarker analysis, thus showing general agreement with its significance.

I
Interest
 High level of interest

The high interest score reflects curiosity about the novel combination of transcriptome and ctDNA analysis and its implications for treatment outcomes, as evident from enthusiastic language and calls to access full articles.

E
Engagement
 Moderate level of engagement

Posts demonstrate moderate depth, with some discussing specific methods like the use of VIGex and circulating tumor DNA, while others merely share links or superficial summaries.

I
Impact
 Moderate level of impact

The discussions suggest the findings could influence future research and clinical practice, but emphasis remains on the potential rather than confirmed change, leading to a moderate impact score.

Social Mentions

YouTube

1 Videos

Bluesky

1 Posts

Twitter

11 Posts

News

4 Articles

Metrics

Video Views

45

Total Likes

20

Extended Reach

30,016

Social Features

17

Timeline: Posts about article

Top Social Media Posts

Posts referencing the article

Biomarker Analysis Predicts Pembrolizumab Outcomes in Solid Tumors

Biomarker Analysis Predicts Pembrolizumab Outcomes in Solid Tumors

This study investigates the effectiveness of VIGex, a gene expression classifier, combined with circulating tumor DNA measurements, in predicting clinical outcomes for patients with advanced solid tumors treated with pembrolizumab.

ASCO Podcasts

December 18, 2024

45 views


  • @bibliotecahuvh.bsky.social (Bluesky)

    Combined Transcriptome and Circulating Tumor DNA Longitudinal Biomarker Analysis Associates With Clinical Outcomes in Advanced Solid Tumors Treated With Pembrolizumab scientiasalut.gencat.cat/handle/11351... #ScientiaVH
    view full post

    February 14, 2025

  • BibliotecaHUVH
    @BibliotecaHUVH (Twitter)

    Combined Transcriptome and Circulating Tumor DNA Longitudinal Biomarker Analysis Associates With Clinical Outcomes in Advanced Solid Tumors Treated With Pembrolizumab https://t.co/IWShawSIlJ #ScientiaVH
    view full post

    February 14, 2025

  • Arantxa Mena
    @Arantxa1976 (Twitter)

    RT @AhernandoCalvo:
    view full post

    September 5, 2024

    3

  • Augusto_Valdivia
    @Augusto_AVB (Twitter)

    RT @AhernandoCalvo:
    view full post

    September 5, 2024

    3

  • Vall d’Hebron Institute of Oncology (VHIO)
    @VHIO (Twitter)

    RT @AhernandoCalvo:
    view full post

    September 4, 2024

    3

  • AHernando_Calvo
    @AhernandoCalvo (Twitter)


    view full post

    September 4, 2024

    17

    3

  • Fundación ECO
    @FundacionECO (Twitter)

    #Paper | Combined Transcriptome and Circulating #Tumor DNA Longitudinal Biomarker Analysis Associates With Clinical Outcomes in Advanced Solid Tumors Treated With #Pembrolizumab @ASCO @JCOPO_ASCO Access the entire article here
    view full post

    September 3, 2024

    1

  • JCO Precision Oncology
    @JCOPO_ASCO (Twitter)

    Combined Transcriptome and Circulating Tumor DNA Longitudinal Biomarker Analysis Associates With Clinical Outcomes in Advanced Solid Tumors Treated With Pembrolizumab: https://t.co/OY1pWxdnUb
    view full post

    September 3, 2024

  • FETTCC Fundación E. Tto. Tumores Cabeza y Cuello
    @FundacionTTCC (Twitter)

    RT @ttccgroup: Combined Transcriptome and Circulating Tumor DNA Longitudinal Biomarker Analysis Associates With Clinical Outcomes in Advanc…
    view full post

    August 30, 2024

    2

  • SECOMCyC
    @SECOMmxf (Twitter)

    RT @ttccgroup: Combined Transcriptome and Circulating Tumor DNA Longitudinal Biomarker Analysis Associates With Clinical Outcomes in Advanc…
    view full post

    August 29, 2024

    2

  • TTCC-GrupoTratamiento Tumores Cabeza y Cuello
    @ttccgroup (Twitter)

    Combined Transcriptome and Circulating Tumor DNA Longitudinal Biomarker Analysis Associates With Clinical Outcomes in Advanced Solid Tumors Treated With Pembrolizumab | JCO Precision Oncology https://t.co/BmPG2PzfSl
    view full post

    August 29, 2024

    2

    2

  • BibliotecaHUVH
    @BibliotecaHUVH (Twitter)

    Combined Transcriptome and Circulating Tumor DNA Longitudinal Biomarker Analysis Associates With Clinical Outcomes in Advanced Solid Tumors Treated With Pembrolizumab https://t.co/j3oLWgRgWA #hvhebron #onco [Text complet]
    view full post

    August 28, 2024

Abstract Synopsis

  • The study investigates the effectiveness of VIGex, a gene expression classifier, combined with circulating tumor DNA (ctDNA) measurements, in predicting clinical outcomes for patients with advanced solid tumors treated with pembrolizumab, an immunotherapy drug.
  • Results showed that patients classified as VIGexHot had better objective response rates, higher overall survival, and longer progression-free survival compared to other subgroups, especially when combined with changes in ctDNA levels.
  • Incorporating ctDNA data with VIGex classification enhances the ability to predict treatment success, suggesting that this combined biomarker approach could improve personalized treatment strategies for immunotherapy patients.]